# Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct01923181` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01923181](<https://clinicaltrials.gov/study/NCT01923181>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01923181

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 632 participants.

## Technical summary

Registry record NCT01923181. Randomized; double masking; primary purpose treatment. Start 2013-12-02 (actual); primary completion 2014-12-11 (actual). Results posted on 2019-11-05.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 632 participants (enrolled count; ClinicalTrials.gov record NCT01923181, source copy `cardio:ctgov-nct01923181-2021-01-15`, retrieved 2026-10-26)
- Started: 2013-12-02 (actual) (ClinicalTrials.gov record NCT01923181, source copy `cardio:ctgov-nct01923181-2021-01-15`, retrieved 2026-10-26)
- Primary completion: 2014-12-11 (actual) (ClinicalTrials.gov record NCT01923181, source copy `cardio:ctgov-nct01923181-2021-01-15`, retrieved 2026-10-26)
- Completion: 2014-12-11 (actual) (ClinicalTrials.gov record NCT01923181, source copy `cardio:ctgov-nct01923181-2021-01-15`, retrieved 2026-10-26)
- Results first posted: 2019-11-05 (ClinicalTrials.gov record NCT01923181, source copy `cardio:ctgov-nct01923181-2021-01-15`, retrieved 2026-10-26)
- Countries: United States; Austria; Bulgaria; Canada; Denmark; Germany; Israel; Italy; Malaysia; Serbia; South Africa; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT01923181, source copy `cardio:ctgov-nct01923181-2021-01-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01923181-2021-01-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): semaglutide
- Intervention (Drug): semaglutide
- Intervention (Drug): oral placebo
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial (`cardio:pubmed-29049653`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4f29ac34fb264c3736d84cf80fc9f89363fee530730ec1a13204f5fd439449aa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
